Henlius

Henlius’ anti-IL1RAP mAb HLX109 has been approved for clinical trial in Australia, with a study planned in GPP.

Designed to modulate IL-1, IL-33 and IL-36 signaling, HLX109 features a half-life extension design and subcutaneous formulation.

🔗: henlius.com/en/newsd/0/316…

From validation to regulatory approval.

At Henlius, end-to-end regulatory capabilities turn scientific innovation into approved therapies, bringing more treatment options to patients worldwide.

As our global story unfolds, we turn innovation into broader access.

🏆 Henlius shortlisted for 4 awards!
3 nominations linked to #ASTRUM006:
🔹 #ScripAwards: Best Oncology R&D Advance
🔹 #CitelineBiotechAwards: Clinical Trial Result of the Year & Patient-First Award
Plus @Citeline_Awards Biopharma Company of the Year!
🔗：citeline.com/awards/

At #ESMO26, descriptive ASTRIDE results were presented from a U.S. first-line ES-SCLC study. It compared serplulimab + chemotherapy vs. atezolizumab + chemotherapy; no superiority/noninferiority test was planned. Serplulimab is investigational in the U.S.
henlius.com/en/newsd/0/316…

New #HLX43 phase 2 data at #ESMO26! 🔬
In advanced G/GEJ adenocarcinoma, our HLX43 achieved 50% cORR, 90% DCR & 5.6-month mPFS at 3.0 mg/kg.
Grade ≥3 drug-related TEAEs: 29% overall, no related deaths.
Another step toward broader antitumor potential!
🔗: henlius.com/en/newsd/0/315…